MYGN Myriad Genetics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MYGN

Price (delayed)

$4.705

Market cap

$444.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.29

Enterprise value

$531.48M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 15
Relative Valuation: Rel. Valuation: 36
Relative Profitability: Rel. Profitability: 15

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing ...

Highlights
The quick ratio has increased by 36% year-on-year but it has declined by 3.5% since the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ
The debt has grown by 34% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.myriad.com/
Peers: BMRN BIO ABT

Key stats

What are the main financial stats of MYGN

MYGN stock price

How has the Myriad Genetics stock price performed over time
Intraday
6.93%
1 week
11.49%
1 month
-4.76%
1 year
-11.06%
YTD
-23.5%
QTD
4.56%

Financial performance

How have Myriad Genetics's revenue and profit performed over time
Revenue
$829M
Gross profit
$580M
Operating income
-$388.9M
Net income
-$399.9M
Gross margin
70%
Net margin
-48.2%
The net margin has contracted by 9% from the previous quarter
The company's net income fell by 9% QoQ

Price vs fundamentals

How does MYGN's price correlate with its fundamentals

Growth

What is Myriad Genetics's growth rate over time

Valuation

What is Myriad Genetics stock price valuation
P/E
N/A
P/B
1.3
P/S
0.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.64
The EPS has contracted by 9% from the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ
MYGN's price to book (P/B) is 39% lower than its 5-year quarterly average of 2.0 and 19% lower than its last 4 quarters average of 1.5
The P/S is 76% lower than the 5-year quarterly average of 2.1 and 29% lower than the last 4 quarters average of 0.7

Efficiency

How efficient is Myriad Genetics business performance
The return on invested capital has dropped by 183% year-on-year but it has grown by 3.4% since the previous quarter
MYGN's return on equity is down by 37% since the previous quarter
Myriad Genetics's return on assets has decreased by 22% QoQ

Dividends

What is MYGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MYGN.

Financial health

How did Myriad Genetics financials performed over time
Myriad Genetics's total assets is 100% more than its total liabilities
The quick ratio has increased by 36% year-on-year but it has declined by 3.5% since the previous quarter
Myriad Genetics's total assets has decreased by 33% YoY and by 4.7% from the previous quarter
The debt is 37% less than the equity
The debt to equity has soared by 186% year-on-year and by 11% since the previous quarter
The company's equity has shrunk by 52% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.